The AstraZeneca vaccine (Vaxzevria) confers “immunity” to Covid 19 “even after one year from a single dose”. This was established by a study, which will be published in ‘Lancet’, of the University of Oxford. The pre-print results “showed that antibody levels remain elevated for at least a year after a single dose,” AstraZeneca points out in a note. Vaxzevria vaccine “resulted in an up to 18-fold increase in antibody response when the interval between first and second doses was up to 45 weeks, a result measured 28 days after booster.” “With a 45-week dosing interval between the first and second dose, antibody titers were four times higher than in a 12-week interval – the study highlights – demonstrating that a longer period between first dose and booster it is not harmful but it can give stronger immunity “.
Welcome! Log into your account
Recover your password
A password will be e-mailed to you.